Cure Today

Imlunestrant-Based Therapy May Improve Survival Without Progression in Advanced Breast Cancer

Imlunestrant improved PFS in ESR1-mutated breast cancer compared to standard endocrine therapy, but not significantly in the overall population. Combining imlunestrant with Verzenio enhanced PFS in ...
ascopubs.org

Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma.

Prognostic effects of co-occurring TP53 and KRAS aberrations in patients with advanced biliary tract cancer.
Nasdaq

KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab and Chemotherapy in First-Line HER2 ...

KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab and Chemotherapy in First-Line HER2-Positive Advanced Gastric or ...
ascopubs.org

Positron-emission tomography utility for progression-free survival prediction in HER2-positive advanced breast cancer patients treated with pertuzumab, trastuzumab, and docetaxel.

DEFENDOR SPECIAL: Effect of primary prophylaxis with empegfilgrastim on pCR rate after neoadjuvant TCHP in early HER2+ breast cancer patients—Matching-adjusted indirect comparison (MAIC). This is an ...